Jolien Perneel

And that’s a wrap - I successfully defended my PhD last week!

Grateful for everyone who made this journey possible (- and meaningful). It feels a bit strange and surreal, yet incredibly rewarding to close such an important chapter of my life. Excited to see what comes next!

Almost there! 🎓

Excited (and a bit surreal) to be defending my PhD soon!

Welcome to join the defense 👇

The role of endolysosomal progranulin and TMEM106B in neurodegenerative diseases - Molecular Neurodegeneration Although different neurodegenerative diseases are defined by distinct pathological proteins, they share many common features including protein aggregation. Despite this commonality, most current thera...

'The role of #endolysosomal #progranulin and #TMEM106B in neurodegenerative diseases'

Hideyuki Takahashi & Stephen M. Strittmatter

molecularneurodegeneration.biomedcentral.com/articles/10....

Prevail Tx/Lilly's investigational AAV gene therapy PR006 that delivers progranulin into brains of patients w/ rare form of dementia/FTD has shown promise in an early safety trial. Nature Biotech story says 6 companies are pursuing the progranulin pathway to potentially treat frontotemporal dementia

I am so very proud announce my lab's first preprint!!

@xiaoyucaly.bsky.social delves into the mechanisms driving tau distribution:
* Tau sequence driven by connectivity dynamics
* Tau load driven by local factors

Check out her thread below

The neuroscience of defeating dementia | Prof Tara Spires-Jones | TEDxUniversityofStAndrews YouTube video by TEDx Talks

🧠 Can we defeat dementia?

This week, BNA President @tspiresjones.bsky.social took the TEDx stage to explore the powerful neuroscience that could help us do just that.

🎥 Watch her talk here: youtu.be/hJMEAd9ODis

#TEDx #Neuroscience #Dementia #BNA

Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study Mirza et al. show that a variant in the TMEM106B gene confers protection against frontotemporal dementia (FTD) by modifying the effects of FTD mutations—in

Disease-modifying effects of TMEM106B in genetic frontotemporal dementia: a longitudinal GENFI study #RareDisease #Genetics academic.oup.com/brain/advanc...

I'm happy to share that our paper describing our novel TMEM106B overexpression mouse model is now out in Molecular Neurodegeneration 🧠📝.

It’s been a project with highs and lows, and seeing it published is incredibly rewarding. Thanks to everyone who was part of the journey 🙌.

Their findings support a templated, prion-like mechanism of aggregation. This new model will be a powerful tool to study disease and screen potential drug candidates that modify disease progression.

TDP-43 seeding induces cytoplasmic aggregation heterogeneity and nuclear loss of function of TDP-43 Rummens et al. demonstrate that amyloid-like fibrils trigger TDP-43 aggregation and nuclear depletion, key hallmarks of neurodegenerative disorders. This provokes a unique transcriptomic signature wit...

📣 Exciting new paper!

The Da Cruz lab created a novel TDP-43 model by seeding TDP-43 fragments, recapitulating both cytoplasmic aggregation and nuclear clearance — key hallmarks of the pathology.

www.cell.com/neuron/fullt...

Gains in early-onset dementia with progranulin open new paths for drug discovery - Nature Biotechnology The first clinical results in patients with a genetic form of frontotemporal dementia (FTD) show that enhancing progranulin in the brain may halt disease progression. If successful, this potentially d...

A genetic medicine that delivers progranulin into the brains of patients with a rare form of dementia has shown promise in an early safety trial. At least six companies are pursuing the progranulin pathway to treat frontotemporal dementia www.nature.com/articles/s41...
rdcu.be/eboPa